Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 150,000 Shares of Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $0.33, for a total value of $49,500.00. Following the completion of the transaction, the director now owns 15,214,091 shares of the company’s stock, valued at $5,020,650.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Andrew Regan also recently made the following trade(s):

• On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.26, for a total value of $393,666.00.
• On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total value of $251,300.00.
• On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $347,455.00.
• On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.51, for a total value of $18,320.73.
• On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.

Conduit Pharmaceuticals Price Performance

NASDAQ:CDT opened at $0.13 on Friday. The stock has a 50 day moving average of $0.18 and a 200-day moving average of $1.78. Conduit Pharmaceuticals Inc. has a 52 week low of $0.11 and a 52 week high of $22.00.

Conduit Pharmaceuticals (NASDAQ:CDT) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.07) EPS for the quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.